Feedback

EU regulator starts review of Covid-19 antibody drug Sotrovimab

Source : 112 Ukraine

Sotrovimab is a monoclonal antibody, a lab-produced antibody intended to stimulate the immune system by reducing the ability of coronavirus’s spike protein to enter the body’s cells
14:58, 8 May 2021

Open source

The European Medicines Agency has begun an accelerated authorisation process for an experimental coronavirus treatment made by GlaxoSmithKline and Vir BioTechnology. This was reported on the regulator's website. 

The EU drug regulator started a rolling review of Sotrovimab, based on early results from an ongoing study into whether the treatment can prevent hospital admission or death in people who do not yet have severe Covid-19.

The EMA said it had not yet received the complete data and cautioned it is “too early to draw any conclusions about the benefit-risk balance of the medication”.

Related: Ukraine should purchase another five mln doses of Covid-19 vaccine to fully provide population, - Health Minister

Although the agency has approved four vaccines, there are few licensed treatments for coronavirus, especially any that might prevent people with mild Covid-19 from progressing to severe disease.

Sotrovimab is a monoclonal antibody, a lab-produced antibody intended to stimulate the immune system by reducing the ability of coronavirus’s spike protein to enter the body’s cells.

An emergency use authorisation for sotrovimab has also been submitted to regulators in the US and Canada.

As we reported earlier, President of Belarus Alexander Lukashenko said that doctors received a Belarusian vaccine against coronavirus. 

"Yesterday we received our Belarusian vaccine in a test tube. It is another vaccine, different from what we are buying today. As doctors call it, a live vaccine," Lukashenko said.

 
Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more